Completed PHASE3 NCT00345631

Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial

Sponsor: Cordis US Corp.

Conditions Angioplasty, Transluminal, Percutaneous Coronary Coronary Arteriosclerosis Peripheral Arteriosclerosis

Interventions Manual Compression Vascular Closure Device

Updated 8 times since 2017 Last updated: May 25, 2012 Started: Feb 28, 2007 Completion: Sep 30, 2007

A PHASE3 clinical study on Angioplasty, Transluminal, Percutaneous Coronary and Coronary Arteriosclerosis, this trial is completed. The trial is conducted by Cordis US Corp. and has accumulated 8 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cordis US Corp.

Data source: Cordis US Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Camden, United States , Clearwater, United States , Cleveland, United States , Dallas, United States , Indianapolis, United States , Liverpool, United States , New York, United States , Philadelphia, United States , Phoenix, United States , Raleigh, United States and 6 more locations